ProQR Therapeutics (PRQR) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ProQR Therapeutics (PRQR) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.10 of bullish evidence against -0.28 bearish.

ProQR Therapeutics last closed at $1.67, +1.83% on the session.

Against the IVW growth benchmark the position is +0.91% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

ProQR Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks ProQR Therapeutics in the 14th percentile on return on equity, where 100 is best.

ProQR Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $230.73M.

StockMap tracks ProQR Therapeutics as the 217th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite ProQR Therapeutics ranks 201st of 344 in the group, against a group median of -0.21.